Aktivnost' renin-angiotenzinovoy sistemy (RAS) zhirovoy tkani: metabolicheskie effekty blokady RAS
https://doi.org/10.14341/2071-8713-5187
Abstract
The review presents data confirming that fat tissue is a significant source of synthesis of all components of renin-angiotensin
system (RAS). It is proposed that activation of fat tissue RAS components have a local paracrine and autocrine actions on adipocytes,
regulates their growth and differentiation, induces subclinical inflammation and insulin resistance (IR). Thus, hyperactivity of local
RAS in fat tissue is one of the mechanisms of visceral obesity, IR and metabolic syndrome. Use of traditional RAS blocking medications
(angiotensin converting enzyme inhibitors, angiotensin receptor blockers) is followed by IR decrease and prevents from development of
type 2 diabetes mellitus. The perspectives of use of a new RAS blocker from a group of direct rennin inhibitors - aliskiren - for correction
of metabolic abnormalities in visceral obesity are considered.
system (RAS). It is proposed that activation of fat tissue RAS components have a local paracrine and autocrine actions on adipocytes,
regulates their growth and differentiation, induces subclinical inflammation and insulin resistance (IR). Thus, hyperactivity of local
RAS in fat tissue is one of the mechanisms of visceral obesity, IR and metabolic syndrome. Use of traditional RAS blocking medications
(angiotensin converting enzyme inhibitors, angiotensin receptor blockers) is followed by IR decrease and prevents from development of
type 2 diabetes mellitus. The perspectives of use of a new RAS blocker from a group of direct rennin inhibitors - aliskiren - for correction
of metabolic abnormalities in visceral obesity are considered.
References
1. Dihn D.T., Frauman A.G., Jonston C.I., Fabiani M.E. Angiotensin receptors: distribution, signaling and function // Clinical Sci. - 2001. - № 100. - Р. 481-492.
2. Paul M., Mehr A., Kreutz R. Physiology of Local Renin-Angiotensin Systems // Physiol Rev. - 2006. - № 86. - Р. 747-803.
3. Engeli S., Bohnke J., Gorzelniak K. et al. Weight loss and the renin-angiotensinaldosterone system // Hypertension. - 2005. - № 45. - Р. 356-62.
4. Sharma A.M., Janke J., Gorzelniak K. et al. Angiotensin Blockade Prevents Type 2 Diabetes by Formation of Fat Cells // Hypertension. - 2002. - № 40. - Р. 609-612.
5. Lastra-Lastra G., Sowers J.R., Restrepo-Erazo C. et al. Role of Aldosterone and angiotensin II in Insulin Resistance: An Update // Clin Endocrinol. - 2009. - № 71. - Р. 1-6.
6. Tian F., Luo R., Zhao Z. et al. Blockade of the RAS increases plasma adiponectin in subjects with metabolic syndrome and enhances differentiation and adiponectin expression of human preadipocytes // Exp Clin Endocrinol Diabetes. - 2010. - № 118(4). - Р. 258-265.
7. Andraws R., Brown D.L. Effect of inhibition of the renin-angiotensin system on development of type 2 diabetes mellitus (meta-analysis of randomized trials) // Am J Cardiol. - 2007. - № 99. - Р. 1006-1012.
8. Shiigai T., Shichiri M. Late escape from the antiproteinuric effect of ACE inhibitors in nondiabetic renal disease // Am J Kidney Dis. - 2001. - № 37. - Р. 477-83.
9. Шамхалова М.Ш., Трубицына Н.П., Шестакова М.В. Феномен частичного ускользания блокады ангиотензина II у больных сахарным диабетом типа 2 и диабетической нефропатией // Тер. арх. - 2008. - № 1. - С. 49-52.
10. Kitamura N., Takahashi Y., Yamadate S. Angiotensin II receptor blockers decreased blood glucose levels: a longitudinal survey using data from electronic medical records // Cardiovascular Diabetology. - 2007. - № 6. - Р. 26-31.
11. Sanoski C.A., Pharm D. Aliskiren: an oral rennin inhibitor for the treatment of hypertension // Pharmacotherapy. - 2009. - № 29. - Р. 193-212.
12. Parving H.H., Persson F., Lewis J.B. et al. Aliskiren combined with losartan in type 2 diabetes and nephropathy // N Engl J Med. - 2008. - № 358. - Р. 2433-2446.
13. Masaru I., Harumi K., Yumiko T. et al. Direct renin inhibition improved insulin resistance and adipose tissue dysfunction in type 2 diabetic KK-Ay mice // J Hypertens. - 2010. - № 28. - Р. 1471-1481.
14. Dong Y.F., Liu L., Kataoka K. et al. Aliskiren prevents cardiovascular complications and pancreatic injury in a mouse model of obesity and type 2 diabetes // Diabetologia. - 2010. - № 53. - Р. 180-191.
15. Prescott M.F., Boye S.W., Le Breton S. et al. Antihypertensive efficacy of the direct renin inhibitor aliskiren when added to hydrochlorothiazide treatment in patients with extreme obesity and hypertension // J Am Coll Cardiol. - 2007. - № 49 (Suppl A). - Р. 370A. Abstract 1014-169.
Review
For citations:
Aktivnost' renin-angiotenzinovoy sistemy (RAS) zhirovoy tkani: metabolicheskie effekty blokady RAS. Obesity and metabolism. 2011;8(1):21-25. (In Russ.) https://doi.org/10.14341/2071-8713-5187
Views:
915
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
